1.10
+0.04(+3.77%)
Currency In USD
| Previous Close | 1.06 |
| Open | 1.09 |
| Day High | 1.11 |
| Day Low | 1.05 |
| 52-Week High | 3.43 |
| 52-Week Low | 0.66 |
| Volume | 753,973 |
| Average Volume | 2.13M |
| Market Cap | 126.86M |
| PE | -0.83 |
| EPS | -1.33 |
| Moving Average 50 Days | 1.23 |
| Moving Average 200 Days | 1.15 |
| Change | 0.04 |
If you invested $1000 in Fate Therapeutics, Inc. (FATE) 10 years ago, it would be worth $260.66 as of November 26, 2025 at a share price of $1.1. Whereas If you bought $1000 worth of Fate Therapeutics, Inc. (FATE) shares 5 years ago, it would be worth $18.99 as of November 26, 2025 at a share price of $1.1.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference
GlobeNewswire Inc.
Yesterday at 1:00 PM GMT
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell
Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy
GlobeNewswire Inc.
Oct 26, 2025 3:30 PM GMT
As of a September 25, 2025 data cut-off-date, 10 patients with treatment-refractory, moderate-to-severe Systemic Lupus Erythematosus (SLE) were treated with a single dose of FT819 with less-intensive or no conditioning chemotherapy Favorable safety p
Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer
GlobeNewswire Inc.
Oct 14, 2025 12:00 PM GMT
SAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE) (the Company), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular im